Research Article

HPTLC-Densitometric Analysis of Eperisone Hydrochloride and Paracetamol in Their Combined Tablet Dosage Form

Nirav Uchadadiya, Falgun Mehta, and Pinak Sanchaniya

Department of Pharmaceutical Chemistry and Analysis, Indukaka Ipcowala College of Pharmacy, New Vallabh Vidyanagar, Gujarat 388121, India

Correspondence should be addressed to Nirav Uchadadiya; nikup982@gmail.com

Received 28 February 2013; Accepted 16 April 2013

Academic Editor: Irene Panderi

Copyright © 2013 Nirav Uchadadiya et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A simple, precise, accurate, and reliable HPTLC method has been developed and validated for the analysis of EPE-Eperisone hydrochloride and PCM-Paracetamol in their combined dosage form. Identification and analysis were performed on 100 mm × 100 mm layer thickness 0.2 mm, precoated silica gel G_{60}-F_{254} aluminum sheet, prewashed with methanol, and dried in an oven at 50°C for 5 min. Toluene : methanol : ethyl acetate : glacial acetic acid (4:3.5:2.5:0.05) (v/v/v/v) was used as mobile phase. Calibration plots were established showing the dependence of response (peak area) on the amount chromatographed. The validated calibration ranges were 200–700 ng/spot and 1300–4550 ng/spot for EPE and PCM with correlation coefficient (R^2) 0.994 and 0.996, respectively. Average % recovery was between 98.61–100.94% and 99.18–100.57% for EPE and PCM, respectively. The spots were scanned at 248 nm in a reflectance mode. The proposed method was validated as per ICH guidelines and successfully applied to the estimation of EPE and PCM in their combined tablet dosage form.

1. Introduction

EPE is chemically (2RS)-1-(4-ethylphenyl)-2-methyl-3-(1-piperidinyl)propan-1-one and hydrochloride (1:1) (Figure 1(a)) [1, 2]. Eperisone HCl is a centrally acting muscle relaxant; it acts at the level of spinal cord by blocking sodium channels and calcium channels. Eperisone HCl exerts its spinal reflex inhibitory action predominantly via a presynaptic inhibition of the transmitter release from the primary afferent endings via a combined action on voltage-gated sodium and calcium channels. Eperisone HCl increases the blood supply to skeletal muscles; this action is noteworthy since a muscle contracture may compress the small blood vessels and induce an ischemia leading to release of pain stimulating compounds [3]. EPE is official in Japanese Pharmacopoeia [1]. Chemically PCM is N-(4-hydroxyphenyl)acetamide (Figure 1(b)). Paracetamol is a weak inhibitor of PG-Prostaglandin synthesis of COX-1 and COX-2. Cyclooxygenase serves as a pain activator, is responsible for the biosynthesis of prostaglandins, is used for the relief of headaches, fever, pains, and is a major ingredient in numerous cold and flu remedies [4]. Paracetamol is official in Japanese Pharmacopoeia [1], British Pharmacopoeia [5], United States Pharmacopoeia [6], and Indian Pharmacopoeia [7].

The review of the literature revealed that analytical methods involving spectrophotometry [8], LC-ESI-MS [9], have been reported for EPE in single form and in combination with other drugs. Several analytical methods have been reported for PCM in single form and in combination with other drugs including spectrophotometry [10–14], HPLC [15–17], and HPTLC [18, 19].

To the best of our knowledge, there is no published HPTLC method for this combination. So, the present paper describes a simple, accurate, and precise method for simultaneous estimation of EPE and PCM in combined tablet dosage form by HPTLC method. The developed method was validated in accordance with ICH guidelines [20] and successfully employed for the assay of EPE and PCM in their combined dosage form.
2. Materials and Methods

2.1. Reagents and Chemicals. Analytically pure EPE and PCM were kindly provided by Macleods Pharmaceuticals Ltd., Mumbai, Maharashtra, India, and Elysium Pharmaceutical Ltd., Vadodara, Gujarat, India, respectively, as gratis samples. Analytical grade methanol was purchased from SRL limited, Mumbai, India. Tablet of EPE and PCM in combined dosage form, MYOSONE PLUS, with a 50 mg EPE and 325 mg PCM label claim, manufactured by Macleods Pharmaceuticals Ltd., was procured from local market.

2.2. Instrumentation and Conditions. Chromatography was performed on 100 mm × 100 mm on precoated silica gel G₆₀-F₂₅₄ aluminium sheet (E. Merck, Mumbai, India). Before use the plates were washed with methanol then dried at room temperature. Samples were applied as 6 mm bands by means of a Camag Linomat V (Muttenz, Switzerland) sample applicator equipped with 100 μL syringe; operated with settings of band length, 6 mm; distance between bands, 5 mm; distance from the plate edge, 10 mm; and distance from the bottom of the plate, 10 mm. The constant application rate was 15 s L⁻¹, and a nitrogen aspirator was used. Ascending development of plate, migration distance 70 mm was performed at ambient temperature with Toluene : methanol : ethyl acetate : glacial acetic acid (4:3.5:2.5:0.05) (v/v/v/v), as mobile phase in a 10 cm × 10 cm Camag twin-trough chamber previously saturated for 15 min. After development the plates were dried with hot-hair dryer and viewed in a CAMAG UV cabinet. Densitometric scanning at 272 nm was then performed with a Camag TLC Scanner 3 equipped with winCATS 3.2.1 software. The scanning rate was 20 mm s⁻¹. The source of radiation used was the deuterium lamp.

2.3. Calibration

2.3.1. Eperisone Hydrochloride (50 μg/mL) and Paracetamol (325 μg/mL) Standard Stock Solution. Standard EPE 50 mg and PCM 325 mg were weighed and transferred to a 100 mL volumetric flask and dissolved in methanol. The flask was sonicated, and volume was made up to the mark with methanol to give a solution containing 50 μg/mL EPE and 325 μg/mL PCM.

2.3.2. Calibration Curve for EPE and PCM. Semiautomatic spotter was used containing a syringe having capacity of 100 μL. Mixed stock solution having concentration of 50 μg/mL of EPE and 325 μg/mL PCM was filled in the syringe, and under nitrogen stream, it was applied in the form of band of desired concentration range for each drug on a single plate having concentration of 200 to 700 ng/spot for EPE and 1300 to 4550 ng/spot for PCM. Plate was developed using the above-mentioned conditions. Plots of peak area versus concentration for both drugs were obtained.

2.4. Analysis of Marketed Formulation. Twenty tablets were weighed accurately; average weight was found and finely powered. A quantity equivalent to 50 mg EPE and 325 mg PCM was accurately weighed and transferred to volumetric flask of 100 mL capacity. 80 mL of methanol was transferred to this volumetric flask and sonicated for 20 min to dissolve the drug. Resulting solution was filtered through Whatman filter paper (0.45 μm) into a 100 mL volumetric flask. The flask was shaken, and volume was made up to the mark with methanol to give a solution containing 500 μg/mL of EPE and 3250 μg/mL of PCM. One mL of this aliquot was added to 10 mL volumetric flask, and volume was made up to the mark with methanol to give a solution containing 50 μg/mL EPE and 325 μg/mL PCM.

2.5. Validation of the Method

2.5.1. Linearity and Range of the HPTLC Method. Calibration graphs were constructed by plotting peak areas versus concentrations of EPE and PCM, and the regression equations were calculated. The calibration graphs were plotted over 6 different concentrations in the range of 200–700 ng/spot for EPE and 1300–4550 ng/spot for PCM by applying different volumes stock solution containing EPE and PCM (50 μg/mL of EPE and 325 μg/mL PCM). The calibration graphs were developed by plotting peak area versus concentrations (n = 6) with the help of the winCATS software.

2.5.2. Accuracy (Recovery). Known amounts of standard solution of EPE (300, 400, and 500 ng/spot) and PCM (2050, 2600, and 3250 ng/spot) for the HPTLC method were added
Table 2

| Concentration (ng/spot) | Area mean ± S.D. (n = 6) | CV  |
|-------------------------|--------------------------|-----|
| **Result of calibration readings for EPE by HPTLC method** |
| 200                     | 1194.33 ± 13.80821       | 1.15|
| 300                     | 1675.967 ± 14.6988       | 0.87|
| 400                     | 2093.35 ± 17.86894       | 0.85|
| 500                     | 2504.867 ± 35.20316      | 1.4 |
| 600                     | 3171.433 ± 29.04952      | 0.91|
| 700                     | 3645.45 ± 23.91458       | 0.66|
| **Result of calibration readings for PCM by HPTLC method** |
| 1300                    | 9373.983 ± 86.3672       | 0.92|
| 1950                    | 11511.37 ± 122.5659      | 1.06|
| 2600                    | 13646.1 ± 86.2213        | 0.63|
| 3250                    | 16556.83 ± 104.0746      | 0.62|
| 3900                    | 18071.97 ± 129.3408      | 0.71|
| 4550                    | 20566.1 ± 110.7175       | 0.53|

Table 3: Determination of accuracy.

| % Level | Amount added (ng/spot) | Amount recovered (ng/spot) (n = 3) | % Recovered ± S.D |
|---------|------------------------|------------------------------------|-------------------|
|         | EPE                    | PCM                                | EPE               | PCM               |
| 50      | 300                    | 2050                               | 302.82            | 2057.17           | 100.94 ± 0.89 | 100.35 ± 0.41 |
| 100     | 400                    | 2600                               | 394.44            | 2578.68           | 98.61 ± 0.74 | 99.18 ± 0.50 |
| 150     | 500                    | 3250                               | 492.95            | 3268.52           | 98.59 ± 0.57 | 100.57 ± 0.93 |

Figure 2: Photograph of developed HPTLC plate of EPE and PCM at 248 nm.

Figure 3: Densitogram of market formulation containing EPE and PCM 400 ng/spot and 2600 ng/spot, respectively.

Figure 4: Overlaid spectrums of EPE and PCM at 248 nm by HPTLC method.

Figure 5: 3D overlain spectra of EPE and PCM by HPTLC method.
to prequantitated sample solutions of tablet dosage forms. The amounts of EPE and PCM were estimated by applying values of peak area to the regression equations of the calibration graph.

2.5.3. Precision. Precisions of the proposed HPTLC methods were determined by analyzing mixed standard solution of EPE and PCM at 3 different concentrations (300, 400, and 500 ng/spot for EPE and 1950, 2600, and 3250 ng/spot for PCM) 3 times in the same day and in 3 different days. The results are reported in terms of coefficient of variance (CV).

2.5.4. Repeatability. Repeatability of method was assessed by applying the same sample solution 6 times on a plate with the automatic spotter using the same syringe and by taking 6 scans of the sample spot for both EPE and PCM (400 ng/spot of EPE and 2600 ng/spot of PCM) without changing the positions of the plate.

2.5.5. Specificity. The specificity of the method was ascertained by analyzing standard drug and sample. The band of both drugs was assessed by comparing the spectra at 3 different levels, that is, peak start (S), peak apex (M), and peak end (E) position of the band.

2.5.6. Limit of Detection and Limit of Quantification. The limit of detection (LOD) and the limit of quantification (LOQ) of the drug were derived by using the following equations as per International Conference on Harmonization (ICH) guidelines which is based on the calibration curve:

\[
\text{LOD} = 3.3 \times \frac{\sigma}{S},
\]

\[
\text{LOQ} = 10 \times \frac{\sigma}{S},
\]

where \(\sigma\) is the standard deviation of \(y\)-intercepts of regression lines and \(S\) is slope of calibration curve.

2.5.7. Robustness. Sample solution was prepared and then analyzed with change in the typical analytical conditions like amount of mobile phase, proportion of mobile phase, saturation time, plate pretreatment, and stability of analytical solution.

3. Results and Discussion

3.1. Method Optimization. Several mobile phases were tried to accomplish good separation of EPE and PCM. Using the mobile phase Toluene : methanol : ethyl acetate : glacial acetic acid (4 : 3.5 : 2.5 : 0.05) (v/v/v/v) and 10 × 10 cm HPTLC silica gel 60 F254 aluminum-backed plates, good separation was attained with retention factor (\(R_f\)) values of 0.26 for EPE and 0.79 for PCM. A wavelength of 248 nm was used for the quantification of the drugs. Figure 2 shows the detection of both of the drugs in their combined dosage form at 248 nm by HPTLC method. Resolution of the peaks with clear baseline separation was found. Figure 3 shows the densitogram of mixture which has a clear baseline. Figure 4 showed a good linearity when overlapped and scanned between 200 nm to 400 nm. Figure 5 shows a 3D overlapped spectrum of both drugs which has good linearity. The system suitability test parameters for the developed method are shown in Table 1.

3.2. Validation of the Proposed Methods

3.2.1. Linearity. Figure 6 shows that linear correlation was obtained between peak areas and concentrations of EPE and PCM in the range of 200–700 ng/spot for EPE with \(R^2 = 0.994\) and 1300–4550 ng/spot for PCM with \(R^2 = 0.996\), respectively, and data are shown in Table 2.

3.2.2. Accuracy. The recovery experiments were performed by the standard addition method. The HPTLC method was found to be accurate with % recovery of 98.61–100.94% for EPE and 99.18–100.57% for PCM, respectively, (Table 3). The high values indicate that the method is accurate.
Table 4: Summary of validation parameters of HPTLC.

| Parameters                      | EPE               | PCM               |
|---------------------------------|-------------------|-------------------|
| Recovery%                       | 99.59–100.94      | 99.18–100.57      |
| Repeatability (CV, n = 6)       | 0.69              | 0.35              |
| Precision (CV)                  |                   |                   |
| Intraday (n = 3)                | 0.69–0.76         | 0.35–0.59         |
| Interday (n = 3)                | 0.77–1.34         | 0.72–1.65         |
| Limit of detection (ng/spot)    | 8.05              | 87.64             |
| Limit of quantitation (ng/spot) | 24.41             | 265.57            |
| Robustness                      | Robust            | Robust            |
| Solvent suitability             | Suitable for 24 hr| Suitable for 24 hr|

Table 5: Assay result of marketed formulation.

| Formulation | Drug | Amount taken (ng/spot) | Amount found (ng/spot) (n = 3) | Labeled claim (mg) | Amount found per tablet (mg) | % Label claim ± SD |
|-------------|------|------------------------|--------------------------------|--------------------|-------------------------------|-------------------|
| MYOSONE PLUS (tablet) | EPE  | 400                    | 395.17                         | 50                 | 49.39                         | 98.79 ± 1.26     |
|             | PCM  | 2600                   | 2544.47                        | 325                | 318.06                        | 97.86 ± 0.84     |

3.2.3. **Repeatability.** The CV values for EPE and PCM were found to be 0.69 and 0.35, respectively. The CV values were found to be <1%, which indicates that the proposed methods are repeatable.

3.2.4. **Precision.** The CV values were found to be <2%, which indicates that the proposed method is precise.

3.2.5. **Limit of Detection (LOD) and Limit of Quantification (LOQ).** LOD values for EPE and PCM were found to be 8.05 ng/spot and 87.64 ng/spot, respectively. LOQ values for EPE and PCM were found to be 24.41 ng/spot and 265.57 ng/spot, respectively. These data show that nanogram quantity of both drugs can be accurately determined (Table 4).

3.2.6. **Specificity.** Excipients (Starch) used in the specificity studies did not interfere with the estimation of either of the drugs by the proposed methods. Hence, the methods were found to be specific for estimation of EPE and PCM.

3.2.7. **Robustness.** Peak area and retention time variation were found to be <1%. Also, no significant change in peak area was observed during 24 hr. No decomposition was observed in either the first or second direction of the 2-dimensional analysis for both drugs on the HPTLC plate. Hence, the method was found to be robust for estimation of EPE and PCM.

3.2.8. **Assay of the Tablet Dosage Form (EPE 50 mg and PCM 325 mg per Tablet).** The proposed validated method was successfully applied to determine EPE and PCM in their tablet dosage form (MYOSONE PLUS). The results obtained for EPE and PCM was comparable with the corresponding labelled amounts (Table 5).

4. **Conclusion**

Thus, the objective of project work was development and comparison of analytical method of EPE and PCM in their combined dosage form. The developed and validated HPTLC method for EPE and PCM was found to be simple, specific, and cost effective and can be routinely applied for analysis of EPE and PCM in their combined dosage form. We can say that HPTLC method is more sensitive giving precise results (interday, intraday) for both drugs, and also HPTLC method is more sensitive in terms of LOD and LOQ. It also requires least solvents for analysis. The proposed method has the advantages of simplicity and convenience for the separation and quantitation of EPE and PCM in combination and can be used for the assay of their dosage form. Also, the low solvent consumption and short analytical run time lead to environmentally friendly chromatographic procedures. The additives usually present in the pharmaceutical formulations of the assayed analytes did not interfere with determination of EPE and PCM. The method can be used for the routine simultaneous analysis of EPE and PCM in pharmaceutical preparations.

**Disclosure**

The usage of this trade mark symbol or company name is for proving the genuinity of the work and not for any another purpose. The authors of the paper, do not have any financial relation with the commercial identity mentioned in the paper.

**Conflict of Interests**

The authors have no conflict of interests or no financial gains in mentioning the company names or trade marks.

**Acknowledgments**

The authors are thankful to Macleods Pharmaceuticals Ltd. (Mumbai, India) and Elysium Pharmaceutical Ltd. (Vadodara, India) for providing gratis sample with the great
pleasure. The authors are also thankful to Principal and Staff of Indukaka Ipcowala College of Pharmacy (New Vallabh Vidyanagar, India) and Director of SICART (New Vallabh Vidyanagar, India) for providing the necessary facilities for research work.

References

[1] Japanese Pharmacopoeia, Government of Japan, The Ministry of Health, Labour and Welfare, 16th edition.
[2] The Merck index, An Encyclopedia of Chemicals, Drugs and Biological, Merck Research Laboratories, 13th edition, 2006.
[3] A. Beltrame, S. Grangiè, and L. Guerra, "Clinical experience with eperisone in the treatment of acute low back pain," Minerva Medicina, vol. 99, no. 4, pp. 347–352, 2008.
[4] K. D. Tripathi, Essentials of Medical Pharmacology, vol. 1, Jaypee Brothers, 5th edition, 2008.
[5] British Pharmacopoeia, vol. 2, Stationery Office on Behalf of the Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK, 2011.
[6] United States Pharmacopoeia and National Formulary, The United States Pharmacopoeia Convention, 24th Asian edition.
[7] Indian Pharmacopoeia, vol. 3, Government of India, Ministry of Health & Family Welfare, the Controller & Publication, Delhi, India, 2010.
[8] P. U. Patel, S. K. Patel, and U. J. Patel, "Spectrophotometric method for simultaneous estimation of eperisone HCl and diclofenac sodium in synthetic mixture," International Research Journal of Pharmacy, vol. 3, no. 9, pp. 203–206, 2012.
[9] Y. Zhang, L. Ding, X. Wei, S. Zhang, and J. Sheng, "Rapid and sensitive liquid chromatography-electrospray ionization-mass spectrometry method for the determination of eperisone in human plasma: method and clinical applications," Journal of Chromatographic Science, vol. 42, no. 5, pp. 254–258, 2004.
[10] M. S. Kondawar, R. R. Shah, J. J. Waghmare, N. D. Shah, and M. K. Malusare, "UV spectrophotometric estimation of paracetamol and lornoxicam in bulk drug and tablet dosage form using multiwavelength method," International Journal of PharmTech Research, vol. 3, no. 3, pp. 1603–1608, 2011.
[11] R. Sawant, L. Bhangale, R. Joshi, and P. Lanke, "Validated spectrophotometric methods for simultaneous estimation of Paracetamol, Domperidone and Tramadol HCl in pure and tablet dosage form," Journal of Chemical Metrology, vol. 4, no. 1, pp. 21–27, 2010.
[12] K. Kalra, S. Naik, G. Jarmal, and N. Mishra, “Spectrophotometric method for simultaneous estimation of paracetamol and domperidone in tablet formulation,” Asian Journal of Research in Chemistry, vol. 2, no. 1, pp. 70–72, 2009.
[13] L. Monser and F. Darghouth, “Simultaneous LC determination of paracetamol and related compounds in pharmaceutical formulations using a carbon-based column,” Journal of Pharmaceutical and Biomedical Analysis, vol. 27, no. 6, pp. 851–860, 2002.
[14] N. P. Dudhane, M. J. Umekar, and R. T. Lohiya, “Validated RP-HPLC method for estimation of metoclopramide hydrochloride and paracetamol in solid dosage form,” Journal of Pharmaceutical Research, vol. 3, no. 12, pp. 3064–3066, 2010.
[15] A. Yadav, R. Singh, S. Mathur, P. Saini, and G. Singh, “A simple and sensitive HPTLC method for simultaneous analysis of domperidone and paracetamol in tablet dosage forms,” Journal of Planar Chromatography, vol. 22, no. 6, pp. 421–424, 2009.
[16] P. B. Deshpanday, V. S. Gandhi, and S. Y. Bhangale, “HPTLC method for simultaneous estimation of etoricoxib and paracetamol in combined tablet dosage,” Journal of Pharmaceutical and Biomedical Analysis, vol. 3, pp. 1–5, 2010.
[17] ICH Harmonized Tripartite Guidelines, Validation of Analytical Procedures: Text and Methodology, Q2 (R1), Geneva, Switzerland, 2005.
